Drug-resistant tuberculosis

This phase 3 trial tests whether a 6-month combination of five drugs (bedaquiline, delamanid, delpazolid, levofloxacin, and pyrazinamide) works as well as standard treatment for rifampicin-resistant tuberculosis in adults and adolescents aged 15 and older in South Africa. The stu…

This study compares two common antibiotic combinations—vancomycin with piperacillin/tazobactam versus vancomycin with meropenem—to see which is less harmful to the kidneys. About 852 hospitalized adults with serious infections will be randomly assigned to one of the two combos. T…

This study tests a new 6-month treatment called BPaLM for people with multidrug-resistant tuberculosis (MDR-TB). The goal is to see if it works as well as the current 18+ month regimen. About 55 adults in France will receive the shorter treatment, and their outcomes will be compa…

This study tests whether adding acetohydroxamic acid (AHA) to a short-course antibiotic regimen can safely and effectively treat multidrug-resistant tuberculosis (MDR-TB). About 120 adults with confirmed MDR-TB will receive either AHA or a placebo alongside standard drugs. The go…

This study tests whether placing one-way valves in the lungs can shrink cavities caused by drug-resistant tuberculosis (TB) or nontuberculous mycobacteria (NTM) infections. The valves block airflow into the cavity, creating a low-oxygen environment that may slow or stop bacterial…

This phase 3 trial tests a 9-month, all-oral combination of four drugs (BLMZ) for people aged 12 and older with rifampicin-resistant tuberculosis. The goal is to see if this shorter regimen leads to a cure without the need for injections. Participants take the pills daily or week…

This study tests whether a 6-month combination of four drugs (bedaquiline, delamanid, linezolid, and levofloxacin) works as well as the standard longer treatment for drug-resistant tuberculosis. Fifty-two adults in Hubei, China will be randomly assigned to either the short or sta…

This study tests a 6-month treatment regimen containing pretomanid for people with drug-resistant tuberculosis who also have type 2 diabetes. Researchers will compare how well the treatment works and how safe it is in diabetic patients versus non-diabetic patients. The goal is to…

This trial tests a new DNA test that reads drug resistance directly from sputum samples in people with multidrug-resistant tuberculosis (MDR-TB). The goal is to see if this test helps doctors prescribe at least five effective drugs within 14 days of diagnosis, compared to current…

This large study in five countries will test new, portable diagnostic tools for tuberculosis (TB) that use tongue swabs and AI-assisted chest X-rays. The goal is to see if these faster, easier tests can find more TB cases, especially in people who have no symptoms or can't produc…

This observational study will look at 10,000 adults in intensive care units (ICUs) around the world during a single 24-hour period. Researchers want to find out how common infections and antibiotic-resistant bacteria are, how they are treated, and how patients recover. No new tre…

This research project aims to understand why older adults get more infections and why those infections can be more serious. By following 23,000 people aged 60 and older, scientists will collect health data and samples like blood and stool to study how the immune system changes wi…

This study looks at how people diagnosed with tuberculosis (TB) in rural and coastal areas of Southwest England experience stigma. Researchers will interview 20 patients to understand how stigma affects their lives and access to care. The goal is to develop better ways to support…

This early-stage study will give a single dose of the experimental antibiotic gepotidacin to 20 hospitalized children aged 2 to 12 who are already receiving standard antibiotics for a bacterial infection or as a preventive measure. Researchers will measure how the drug moves thro…

This study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…

This study will follow 300 adults with severe infections in the ICU to see how levels of specialized pro-resolving mediators (SPMs)—natural molecules that help stop inflammation—change over time. Researchers will use blood samples already collected during routine care, so no extr…